MA22894A1 - Procede de preparation d'un vaccin. - Google Patents

Procede de preparation d'un vaccin.

Info

Publication number: MA22894A1
Authority: MA; Morocco
Prior art keywords: vaccine; preparation
Prior art date: 1992-05-23

Application number

MA23192A

Other languages

English (en)

Inventor

Petre Jean

Hauser Pierre

Original Assignee

Smithkline Beecham Biolog

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-05-23

Filing date

1993-05-21

Publication date

1993-12-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26300928&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA22894(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1992-05-23 Priority claimed from GB929211081A external-priority patent/GB9211081D0/en

1992-06-23 Priority claimed from GB929213308A external-priority patent/GB9213308D0/en

1993-05-21 Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog

1993-12-31 Publication of MA22894A1 publication Critical patent/MA22894A1/fr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
- A61K39/0017—Combination vaccines based on whole cell diphtheria-tetanus-pertussis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
- A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/099—Bordetella
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
- C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Virology (AREA)
Pharmacology & Pharmacy (AREA)
Mycology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Microbiology (AREA)
Immunology (AREA)
Epidemiology (AREA)
Communicable Diseases (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Gastroenterology & Hepatology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)

MA23192A 1992-05-23 1993-05-21 Procede de preparation d'un vaccin. MA22894A1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB929211081A GB9211081D0 (en)	1992-05-23	1992-05-23	Vaccines
GB929213308A GB9213308D0 (en)	1992-06-23	1992-06-23	Vaccine

Publications (1)

Publication Number	Publication Date
MA22894A1 true MA22894A1 (fr)	1993-12-31

Family

ID=26300928

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA23192A MA22894A1 (fr)	1992-05-23	1993-05-21	Procede de preparation d'un vaccin.

Country Status (30)

Country	Link
US (1)	US6013264A (fr)
EP (4)	EP0835663B1 (fr)
JP (1)	JP3626996B2 (fr)
KR (1)	KR100287083B1 (fr)
CN (2)	CN1136918C (fr)
AP (1)	AP567A (fr)
AT (2)	ATE444079T1 (fr)
AU (5)	AU4315693A (fr)
CA (1)	CA2136429C (fr)
CY (1)	CY2614B2 (fr)
CZ (1)	CZ283910B6 (fr)
DE (4)	DE69334297D1 (fr)
DK (2)	DK0835663T3 (fr)
ES (2)	ES2334181T3 (fr)
FI (1)	FI945483L (fr)
HU (1)	HU220236B (fr)
IL (1)	IL105770A (fr)
LU (2)	LU91658I2 (fr)
MA (1)	MA22894A1 (fr)
MX (1)	MX9302982A (fr)
MY (1)	MY110665A (fr)
NO (1)	NO309675B1 (fr)
NZ (1)	NZ253065A (fr)
PT (1)	PT835663E (fr)
RU (1)	RU2160120C2 (fr)
SG (1)	SG48365A1 (fr)
SI (1)	SI9300271A (fr)
SK (1)	SK280702B6 (fr)
UA (1)	UA40596C2 (fr)
WO (1)	WO1993024148A1 (fr)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9503863D0 (en) *	1995-02-25	1995-04-19	Smithkline Beecham Biolog	Vaccine compositions
US6696065B1 (en)	1995-05-04	2004-02-24	Aventis Pastuer Limited	Acellular pertussis vaccines and methods of preparation thereof
FR2734484B1 (fr)	1995-05-24	1997-06-27	Pasteur Merieux Serums Vacc	Composition vaccinale liquide et procede de fabrication
US20030157129A1 (en) *	1995-06-23	2003-08-21	Smithkline Beecham Biologicals S.A.	Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein
AU696338B2 (en)	1995-06-23	1998-09-10	Smithkline Beecham Biologicals (Sa)	A vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate
US20020054884A1 (en)	1995-06-23	2002-05-09	Smithkline Beecham Biologicals, Sa	Vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate
IL127847A (en) *	1996-07-02	2004-06-01	Connaught Lab	Polio-karma vaccine vaccines, valuable pertussis
US20010014331A1 (en)	1996-11-07	2001-08-16	Smithkline Beecham Biologicals S.A.	Acellular pertussis vaccine with diphthriae-and tetanus-toxoids
GB9623233D0 (en) *	1996-11-07	1997-01-08	Smithkline Beecham Biolog	Vaccine composition
CU22629A1 (es) *	1997-03-06	2000-12-22	Ct Ingenieria Genetica Biotech	Formulaciones inmunopotenciadoras para uso vacunal
JP2002508748A (ja) *	1997-05-01	2002-03-19	カイロンコーポレイション	アジュバントとしてのウイルス様粒子の使用
DK1028750T3 (da) *	1997-09-15	2006-05-22	Sanofi Pasteur Msd	Fremgangsmåde til fremstilling af multivalente vacciner
NZ506602A (en) *	1998-03-09	2003-02-28	Smithkline Beecham Biolog S	Combined vaccine compositions against hepatitis B virus and herpes simplex virus and possibly also epstein bar virus, hepatitis A & C viruses, human papilloma virus, varicella zoster virus, human cytomegalovirus, and toxoplasma gondii
GB9806456D0 (en) *	1998-03-25	1998-05-27	Smithkline Beecham Biolog	Vaccine composition
US20030049268A1 (en)	1998-05-01	2003-03-13	Smithkline Beecham Biologicals S.A.	Novel composition
GB9809507D0 (en) *	1998-05-01	1998-07-01	Smithkline Beecham Biolog	Novel composition
RU2130779C1 (ru) *	1998-07-31	1999-05-27	Акционерное общество закрытого типа Научно-производственная компания "Комбиотех Лтд"	Комбинированная вакцина для иммунопрофилактики вирусного гепатита в, столбняка и дифтерии
RU2130778C1 (ru) *	1998-07-31	1999-05-27	Акционерное общество закрытого типа НПК "Комбиотех Лтд"	Комбинированная вакцина для иммунопрофилактики вирусного гепатита в, столбняка, дифтерии и коклюша
AT408615B (de) *	1998-09-15	2002-01-25	Immuno Ag	Neue influenzavirus-impfstoffzusammensetzung
SI1126876T1 (sl)	1998-10-16	2007-08-31	Glaxosmithkline Biolog Sa	Adjuvantni sistemi in vakcine
CN1053590C (zh) *	1998-10-19	2000-06-21	卫生部长春生物制品研究所	冻干甲型肝炎减毒活疫苗及其保护剂
CU22871A1 (es)	1998-12-02	2003-10-21	Ct Ingenieria Genetica Biotech	Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal
US6974581B1 (en) *	1998-12-15	2005-12-13	Aventis Pasteur Limited	Multi-component vaccine comprising at least two antigens from haemophilus influenzae to protect against disease
US7098309B2 (en) *	1998-12-23	2006-08-29	Merck & Co., Inc.	Recombinant hepatitis B surface antigen
US7172762B1 (en) *	1999-01-29	2007-02-06	Pfizer Inc.	Erysipelothrix rhusiopathiae antigens and vaccine compositions
GB9923060D0 (en)	1999-09-29	1999-12-01	Chiron Spa	Vaccine
GB9928196D0 (en)	1999-11-29	2000-01-26	Chiron Spa	Combinations of B, C and other antigens
KR100374813B1 (ko) *	2000-04-07	2003-03-03	녹십자백신 주식회사	디프테리아, 파상풍 톡소이드, 정제백일해 및비형간염표면항원을 포함한 4가 혼합백신 및 그 제조 방법
GB0108364D0 (en)	2001-04-03	2001-05-23	Glaxosmithkline Biolog Sa	Vaccine composition
EP2279748A1 (fr)	2000-06-29	2011-02-02	SmithKline Beecham Biologicals S.A.	Composition vaccinale multivalente
KR100385711B1 (ko) *	2000-07-05	2003-05-27	녹십자백신 주식회사	디프테리아, 파상풍 톡소이드와 백일해균 및ｂ형간염표면항원을 포함한 4가 혼합백신 및 그 제조방법
KR100401423B1 (ko) *	2001-01-10	2003-10-17	주식회사 엘지생명과학	혼합 백신의 제조 방법
AP1897A (en)	2001-01-23	2008-10-10	Aventis Pasteur	Multivalent Meningococcal polysaccharide-Protein Conjugate Vaccine.
AU2007200116A1 (en) *	2001-04-03	2007-02-01	Glaxosmithkline Biologicals S.A.	Vaccine composition
GB0115176D0 (en)	2001-06-20	2001-08-15	Chiron Spa	Capular polysaccharide solubilisation and combination vaccines
GB0118249D0 (en)	2001-07-26	2001-09-19	Chiron Spa	Histidine vaccines
CA2452720C (fr) *	2001-07-26	2012-04-17	Chiron S.R.L.	Vaccins comprenant des adjuvants aluminium et histidine
IL145926A0 (en) *	2001-10-15	2002-07-25	Mor Research Applic Ltd	Peptide epitopes of mimotopes useful in immunomodulation
CU23031A1 (es) *	2002-01-24	2005-02-23	Ct Ingenieria Genetica Biotech	Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes
CA2480690A1 (fr) *	2002-03-28	2003-10-09	Brenntag Biosector A/S	Compositions de vaccins a proteines/adn combines
GB0223355D0 (en) *	2002-10-08	2002-11-13	Chiron Spa	Vaccine
JP4579156B2 (ja)	2002-11-01	2010-11-10	グラクソスミスクラインバイオロジカルズソシエテアノニム	免疫原組成物
EP2191844B1 (fr)	2003-01-30	2014-03-05	Novartis AG	Vaccins injectables contre les multiples serogroupes du meningocoque
RU2238105C1 (ru) *	2003-03-14	2004-10-20	Закрытое акционерное общество научно-производственная компания "Комбиотех"	Рекомбинантная вакцина для профилактики вирусного гепатита в (варианты)
RU2233673C1 (ru) *	2003-03-31	2004-08-10	Закрытое акционерное общество научно-производственная компания "Комбиотех"	Комбинированная вакцина для иммунопрофилактики коклюша, дифтерии, столбняка и вирусного гепатита в и д
RU2233672C1 (ru) *	2003-03-31	2004-08-10	Закрытое акционерное общество научно-производственная компания "Комбиотех"	Комбинированная вакцина для иммунопрофилактики вирусного гепатита в и д, столбняка и дифтерии
GB0313916D0 (en)	2003-06-16	2003-07-23	Glaxosmithkline Biolog Sa	Vaccine composition
CA2885040C (fr)	2003-10-02	2018-10-30	Novartis Vaccines And Diagnostics S.R.L.	Vaccins liquides contre de multiples serogroupes meningococciques
GB0409745D0 (en)	2004-04-30	2004-06-09	Chiron Srl	Compositions including unconjugated carrier proteins
CN1984679B (zh)	2004-06-04	2013-05-15	美国政府健康及人类服务部	制备免疫原性结合物的方法
GB0505518D0 (en) *	2005-03-17	2005-04-27	Chiron Srl	Combination vaccines with whole cell pertussis antigen
GB0505996D0 (en)	2005-03-23	2005-04-27	Glaxosmithkline Biolog Sa	Fermentation process
SG175456A1 (en)	2005-04-18	2011-11-28	Novartis Vaccines & Diagnostic	Expressing hepatitis b virus surface antigen for vaccine preparation
KR101408113B1 (ko)	2005-06-27	2014-06-16	글락소스미스클라인 바이오로지칼즈 에스.에이.	백신 제조 방법
GB0517719D0 (en) *	2005-08-31	2005-10-05	Chiron Srl	Vaccines containing pili
EP1931380A2 (fr)	2005-09-01	2008-06-18	Novartis Vaccines and Diagnostics GmbH & Co. KG	Vaccination multiple comprenant des meningocoques du serogroupe c
GB0522765D0 (en) *	2005-11-08	2005-12-14	Chiron Srl	Combination vaccine manufacture
EP1862176A1 (fr) *	2006-05-31	2007-12-05	Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH	Procédé de production de composition vaccinale
EP1862177A1 (fr) *	2006-06-01	2007-12-05	Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH	Procédé de production de composition vaccinale
GB0616226D0 (en) *	2006-08-15	2006-09-27	Novartis Ag	Processes
GB0616306D0 (en) *	2006-08-16	2006-09-27	Novartis Ag	Vaccines
GB0617602D0 (en) *	2006-09-07	2006-10-18	Glaxosmithkline Biolog Sa	Vaccine
HRP20120557T1 (hr)	2006-09-07	2012-07-31	GlaxoSmithKline@Biologicals@s@a	Kombinirano cjepivo sa smanjenim količinama antigena poliovirusa
EA200970731A1 (ru) *	2007-02-07	2010-02-26	Сигма-Тау Индустрие Фармасьютике Риуните С.П.А.	Рекомбинантные антигены цитомегаловируса человека (hcmv)
MX2009011837A (es)	2007-05-02	2010-04-22	Glaxosmithkline Biolog Sa	Vacuna.
CU23679A1 (es) *	2007-10-30	2011-07-11	Ct Ingenieria Genetica Biotech	Variantes de pertactinas para uso vacunal
PE20100365A1 (es) *	2008-10-24	2010-05-21	Panacea Biotec Ltd	Novedosas vacunas de combinacion con tos ferina de celulas enteras y metodo para su elaboracion
PE20100366A1 (es)	2008-10-24	2010-05-21	Panacea Biotec Ltd	Novedosas composiciones de vacuna con tos ferina acelular asi como el metodo para su elaboracion
GB0822633D0 (en)	2008-12-11	2009-01-21	Novartis Ag	Formulation
GB0822634D0 (en)	2008-12-11	2009-01-21	Novartis Ag	Meningitis vaccines
IT1398927B1 (it)	2009-06-25	2013-03-28	Consorzio Interuniversitario Per Lo Sviluppo Dei Sistemi A Grande Interfase Csgi	Espressione batterica di un gene artificiale per la produzione di crm197 e derivati.
GB0917647D0 (en)	2009-10-08	2009-11-25	Glaxosmithkline Biolog Sa	Expression system
WO2012020326A1 (fr)	2010-03-18	2012-02-16	Novartis Ag	Vaccins adjuvantés contre le méningocoque de sérogroupe b
FR2966044B1 (fr)	2010-10-18	2012-11-02	Sanofi Pasteur	Procede de conditionnement d'un vaccin contenant un adjuvant d'aluminium
NZ611176A (en)	2010-12-02	2015-07-31	Bionor Immuno As	Peptide scaffold design
CN103442730B (zh)	2011-01-05	2016-08-17	巴拉特生物技术国际有限公司	组合七价疫苗
CA2821995C (fr)	2011-01-06	2019-02-12	Bionor Immuno As	Peptides monomeres et multimeres immunogenes contre le vih
GB201105981D0 (en)	2011-04-08	2011-05-18	Glaxosmithkline Biolog Sa	Novel process
SG194886A1 (en) *	2011-05-11	2013-12-30	Riesbeck Healthcare Sweden Ab	Protein f - a novel haemophilus influenzae adhesin with laminin and vitronectin binding properties
WO2013049535A2 (fr)	2011-09-30	2013-04-04	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Vaccin antigrippal
RU2465316C1 (ru) *	2011-10-05	2012-10-27	Общество с ограниченной ответственностью "ГРИТВАК"	Штамм бактерий haemophilus influenzae в №326, стабильный продуцент капсульного полисахарида
EP2592137A1 (fr)	2011-11-11	2013-05-15	Novartis AG	Support de fermentation sans composants dérivés d'animaux pour la production des toxoïdes diphtériques adaptées à l'utilisation du vaccin humain
GB2495341B (en)	2011-11-11	2013-09-18	Novartis Ag	Fermentation methods and their products
DE102011122891B4 (de)	2011-11-11	2014-12-24	Novartis Ag	Fermentationsmedium, das frei von tierischen Bestandteilen ist, zur Herstellung von Diphtherie-Toxoiden zur Verwendung bei der Impfung von Menschen
DE102011118371B4 (de)	2011-11-11	2014-02-13	Novartis Ag	Zur Impfung von Menschen geeignete Zusammensetzung, die ein Diphtherie-Toxoid umfasst, sowie Verfahren zu deren Herstellung
FR2985663B1 (fr) *	2012-01-17	2015-03-27	Sanofi Pasteur	Procede de formulation d'un vaccin contenant au moins deux antigenes susceptibles de s'adsorber sur de l'oxy hydroxyde d'aluminium
US9475848B2 (en)	2012-02-01	2016-10-25	Glaxosmithkline Biologicals S.A.	Fermentation process for producing a virulence factor from bordetella
CN104159603A (zh) *	2012-03-08	2014-11-19	诺华股份有限公司	带有tlr4激动剂的联合疫苗
CA2874923C (fr)	2012-06-06	2021-08-31	Bionor Immuno As	Peptides issus de proteines virales pour l'utilisation en tant qu'immunogenes et reactifs de dosage
SG11201500573RA (en)	2012-08-06	2015-02-27	Glaxosmithkline Biolog Sa	Method for eliciting in infants an immune response against rsv and b. pertussis
US20140037680A1 (en)	2012-08-06	2014-02-06	Glaxosmithkline Biologicals, S.A.	Novel method
AU2013328548A1 (en)	2012-10-12	2015-05-07	Glaxosmithkline Biologicals Sa	Non-cross-linked acellular pertussis antigens for use in combination vaccines
KR102236498B1 (ko)	2013-03-08	2021-04-06	얀센 백신스 앤드 프리벤션 비.브이.	무세포 백일해 백신
US9993534B2 (en)	2013-03-12	2018-06-12	Wisconsin Alumni Research Foundation	Method of treating fungal infection
CA2919773A1 (fr)	2013-08-05	2015-02-12	Glaxosmithkline Biologicals S.A.	Compositions immunogenes en combinaison
AR101256A1 (es)	2014-07-21	2016-12-07	Sanofi Pasteur	Composición vacunal que comprende ipv y ciclodextrinas
WO2017048038A1 (fr) *	2015-09-16	2017-03-23	Lg Life Sciences Ltd.	Composition de vaccin combinée pour administration multiple
WO2018067582A2 (fr)	2016-10-03	2018-04-12	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Immunogènes de peptides de fusion env du vih-1 et leur utilisation
WO2018081832A1 (fr)	2016-10-31	2018-05-03	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Fragments peptidiques de filovirus et leurs utilisations
WO2018176031A1 (fr)	2017-03-24	2018-09-27	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Domaines externes modifiés masqués par le glycane du vih-1, gp120, et leur utilisation
CA3070039A1 (fr)	2017-07-18	2019-01-24	Serum Institute Of India Pvt Ltd.	Composition immunogene a stabilite amelioree, immunogenicite amelioree et moindre reactogenicite, et procede de preparation de cette derniere
EP3697440A1 (fr)	2017-10-16	2020-08-26	The United States of America, as represented by the Secretary, Department of Health and Human Services	Protéines d'enveloppe recombinées du vih-1 et leur utilisation
WO2020043874A1 (fr)	2018-08-31	2020-03-05	Glaxosmithkline Biologicals Sa	Vaccin conjugué contre haemophilus influenzae utilisant une vésicule de membrane externe de bordetella
US12053519B2 (en)	2018-09-23	2024-08-06	The United States Of America, As Represented By The Secretary Department Of Health And Human Services	HIV-1 Env fusion peptide nanoparticle carrier conjugates and their use
JOP20190242A1 (ar)	2018-10-12	2020-04-12	Serum Institute Of India Pvt Ltd	تركيبة لقاح توليفي تشمل فيروس شلل الأطفال ذو جرعة مخفّضة خاملة التنشيط وطريقة لتحضيرها
US12162910B2 (en)	2018-10-22	2024-12-10	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Recombinant gp120 protein with V1-loop deletion
GB2619625B (en)	2019-05-20	2024-04-03	Soligenix Inc	Compositions and Methods of Manufacturing Trivalent Filovirus Vaccines
US12210017B2 (en)	2020-01-08	2025-01-28	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Peptides representing epitopes from filoviruses
WO2021160887A1 (fr)	2020-02-14	2021-08-19	Immunor As	Vaccin contre le coronavirus
WO2021176409A1 (fr)	2020-03-05	2021-09-10	Sanofi Healthcare India Private Limited	Combinaison de conservateurs pour composition de vaccin
US12268738B2 (en)	2021-04-20	2025-04-08	Km Biologics Co., Ltd.	Liquid six combined vaccine composition
US20240277829A1 (en)	2021-08-03	2024-08-22	The U.S.A., As Represented By The Secretary, Department Of Health And Human Services	Hiv-1 vaccination and samt-247 microbicide to prevent hiv-1 infection
EP4169513A1 (fr)	2021-10-19	2023-04-26	GlaxoSmithKline Biologicals S.A.	Composition d'adjuvant comprenant des agonistes du sting
WO2023192835A1 (fr)	2022-03-27	2023-10-05	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Ectodomaines de l'enveloppe du vih-1 recouverts d'une base et leur utilisation
WO2024249626A1 (fr)	2023-05-30	2024-12-05	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Trimères en tandem triple de l'enveloppe du vih-1 et leur utilisation

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS6013718A (ja) *	1983-07-05	1985-01-24	Chemo Sero Therapeut Res Inst	Ｂ型肝炎ワクチン
JPS60193925A (ja) *	1984-03-13	1985-10-02	Chemo Sero Therapeut Res Inst	凍結乾燥製剤化ワクチン
US4624918A (en) *	1984-07-09	1986-11-25	Genentech, Inc.	Purification process for hepatitis surface antigen and product thereof
FI861417A0 (fi)	1985-04-15	1986-04-01	Endotronics Inc	Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav.
US4895800A (en)	1985-11-26	1990-01-23	Phillips Petroleum Company	Yeast production of hepatitis B surface antigen
AP56A (en)	1987-01-30	1989-09-26	Smithkline Biologicals S A	Hepatitis B virus surface antigens and hybrid antigehs containing them.
EP0304578B1 (fr)	1987-06-22	2001-10-24	Medeva Holdings Bv	Peptide contenant l'antigène de surface de l'hépatite B
ATE105858T1 (de)	1987-07-17	1994-06-15	Rhein Biotech Ges Fuer Biotech	Dna-moleküle, die für fmdh-kontrollabschnitte und strukturgene für ein protein mit fmdh-aktivität kodieren, sowie deren anwendung.
JPH085804B2 (ja) *	1988-04-28	1996-01-24	財団法人化学及血清療法研究所	Ａ型及びｂ型肝炎混合アジュバントワクチン
SG48175A1 (en)	1989-07-25	1998-04-17	Smithkline Beecham Biolog	Novel antigens and method for their preparation
EP0427462B1 (fr)	1989-11-06	1996-02-14	SMITHKLINE BEECHAM BIOLOGICALS (S.A.), formerly SMITHKLINE BIOLOGICALS (S.A.)	Procédé
JP3035712B2 (ja)	1990-02-12	2000-04-24	スミスクラインビーチャムバイオロジカルズ（エスア）	新規なワクチンおよびそのための方法
GB9007024D0 (en)	1990-03-29	1990-05-30	Imperial College	Novel vaccine
AU9052091A (en) *	1990-12-20	1992-07-22	Smithkline Beecham Biologicals (Sa)	Vaccines based on hepatitis b surface antigen
CA2067003A1 (fr)	1991-04-29	1992-10-30	Peter J. Kniskern	Vaccin mutant de variante d'antigene de surface d'hbv
EP0533492A3 (en) *	1991-09-18	1994-08-10	Amgen Inc	A hepatitis b vaccine formulation incorporating a bile acid salt
CZ289476B6 (cs) *	1993-03-23	2002-01-16	Smithkline Beecham Biologicals (S.A.)	Očkovací přípravek a způsob jeho výroby
AU696338B2 (en)	1995-06-23	1998-09-10	Smithkline Beecham Biologicals (Sa)	A vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate
RU2130778C1 (ru)	1998-07-31	1999-05-27	Акционерное общество закрытого типа НПК "Комбиотех Лтд"	Комбинированная вакцина для иммунопрофилактики вирусного гепатита в, столбняка, дифтерии и коклюша
KR100385711B1 (ko)	2000-07-05	2003-05-27	녹십자백신 주식회사	디프테리아, 파상풍 톡소이드와 백일해균 및ｂ형간염표면항원을 포함한 4가 혼합백신 및 그 제조방법
KR100401423B1 (ko)	2001-01-10	2003-10-17	주식회사 엘지생명과학	혼합 백신의 제조 방법

1993
- 1993-05-15 EP EP97204034A patent/EP0835663B1/fr not_active Revoked
- 1993-05-15 UA UA94129182A patent/UA40596C2/uk unknown
- 1993-05-15 KR KR1019940704215A patent/KR100287083B1/ko not_active Ceased
- 1993-05-15 RU RU94046145/13A patent/RU2160120C2/ru active IP Right Maintenance
- 1993-05-15 PT PT97204034T patent/PT835663E/pt unknown
- 1993-05-15 AT AT97204034T patent/ATE444079T1/de active
- 1993-05-15 ES ES97204034T patent/ES2334181T3/es not_active Expired - Lifetime
- 1993-05-15 EP EP93912750A patent/EP0642355B1/fr not_active Revoked
- 1993-05-15 FI FI945483A patent/FI945483L/fi not_active Application Discontinuation
- 1993-05-15 SG SG1996009149A patent/SG48365A1/en unknown
- 1993-05-15 DE DE69334297T patent/DE69334297D1/de not_active Expired - Lifetime
- 1993-05-15 AT AT93912750T patent/ATE168271T1/de not_active IP Right Cessation
- 1993-05-15 EP EP10179579A patent/EP2289548A3/fr not_active Withdrawn
- 1993-05-15 NZ NZ253065A patent/NZ253065A/en not_active IP Right Cessation
- 1993-05-15 HU HU9403366A patent/HU220236B/hu unknown
- 1993-05-15 DE DE122010000016C patent/DE122010000016I1/de active Pending
- 1993-05-15 CA CA002136429A patent/CA2136429C/fr not_active Expired - Lifetime
- 1993-05-15 EP EP09171545A patent/EP2156845A1/fr not_active Withdrawn
- 1993-05-15 ES ES93912750T patent/ES2118963T3/es not_active Expired - Lifetime
- 1993-05-15 JP JP50016294A patent/JP3626996B2/ja not_active Expired - Lifetime
- 1993-05-15 AU AU43156/93A patent/AU4315693A/en not_active Abandoned
- 1993-05-15 WO PCT/EP1993/001276 patent/WO1993024148A1/fr not_active Ceased
- 1993-05-15 DK DK97204034.9T patent/DK0835663T3/da active
- 1993-05-15 DK DK93912750T patent/DK0642355T3/da active
- 1993-05-15 SK SK1421-94A patent/SK280702B6/sk not_active IP Right Cessation
- 1993-05-15 CZ CZ942892A patent/CZ283910B6/cs not_active IP Right Cessation
- 1993-05-15 DE DE122010000015C patent/DE122010000015I1/de active Pending
- 1993-05-15 DE DE69319728T patent/DE69319728T2/de not_active Revoked
- 1993-05-20 MY MYPI93000939A patent/MY110665A/en unknown
- 1993-05-20 AP APAP/P/1993/000530A patent/AP567A/en active
- 1993-05-21 SI SI9300271A patent/SI9300271A/sl not_active IP Right Cessation
- 1993-05-21 IL IL10577093A patent/IL105770A/en not_active IP Right Cessation
- 1993-05-21 MA MA23192A patent/MA22894A1/fr unknown
- 1993-05-21 MX MX9302982A patent/MX9302982A/es active IP Right Grant
- 1993-05-22 CN CNB931073197A patent/CN1136918C/zh not_active Ceased
- 1993-05-22 CN CNB031332374A patent/CN1313152C/zh not_active Expired - Lifetime
1994
- 1994-11-22 NO NO944475A patent/NO309675B1/no not_active IP Right Cessation
1996
- 1996-11-25 US US08/755,927 patent/US6013264A/en not_active Expired - Lifetime
1997
- 1997-03-24 AU AU16480/97A patent/AU709406C/en not_active Expired
2002
- 2002-06-25 AU AU50629/02A patent/AU785433B2/en not_active Expired
2007
- 2007-03-16 AU AU2007201162A patent/AU2007201162A1/en not_active Abandoned
2010
- 2010-01-22 AU AU2010200249A patent/AU2010200249B2/en not_active Expired
- 2010-03-03 LU LU91658C patent/LU91658I2/fr unknown
- 2010-03-03 LU LU91659C patent/LU91659I2/fr unknown
2011
- 2011-03-02 CY CY1100003A patent/CY2614B2/xx unknown

Also Published As

Publication number	Publication date
EP2156845A1 (fr)	2010-02-24
UA40596C2 (uk)	2001-08-15
RU2160120C2 (ru)	2000-12-10
AU709406C (en)	2004-04-08
DE69319728T2 (de)	1999-02-04
KR100287083B1 (ko)	2001-04-16
HU9403366D0 (en)	1995-02-28
SK280702B6 (sk)	2000-06-12
EP2289548A2 (fr)	2011-03-02
FI945483A0 (fi)	1994-11-22
HK1011290A1 (en)	1999-07-09
CZ289294A3 (en)	1995-09-13
US6013264A (en)	2000-01-11
AU2007201162A1 (en)	2007-04-19
LU91659I2 (fr)	2010-05-03
CN1136918C (zh)	2004-02-04
DK0835663T3 (da)	2010-02-01
ATE444079T1 (de)	2009-10-15
KR950701822A (ko)	1995-05-17
FI945483A7 (fi)	1995-01-20
IL105770A (en)	1998-08-16
AU709406B2 (en)	1999-08-26
NZ253065A (en)	1996-10-28
NO944475D0 (no)	1994-11-22
HU220236B (hu)	2001-11-28
IL105770A0 (en)	1993-09-22
CZ283910B6 (cs)	1998-07-15
AU1648097A (en)	1997-05-29
DE69334297D1 (de)	2009-11-12
AU4315693A (en)	1993-12-30
PT835663E (pt)	2010-01-04
RU94046145A (ru)	1997-03-27
HUT71791A (en)	1996-02-28
WO1993024148A1 (fr)	1993-12-09
EP0835663A3 (fr)	1999-03-03
SI9300271A (en)	1993-12-31
NO309675B1 (no)	2001-03-12
MX9302982A (es)	1993-12-01
EP2289548A3 (fr)	2012-08-08
DE122010000015I1 (de)	2010-07-08
HK1021142A1 (en)	2000-06-02
EP0642355A1 (fr)	1995-03-15
CN1085450A (zh)	1994-04-20
CA2136429A1 (fr)	1993-12-09
CN1623602A (zh)	2005-06-08
MY110665A (en)	1999-01-30
AP9300530A0 (en)	1993-07-31
AU2010200249A1 (en)	2010-02-11
EP0835663B1 (fr)	2009-09-30
AU5062902A (en)	2002-08-08
CA2136429C (fr)	2001-12-11
AP567A (en)	1996-11-25
ES2334181T3 (es)	2010-03-05
AU2010200249B2 (en)	2012-01-12
EP0642355B1 (fr)	1998-07-15
EP0835663A2 (fr)	1998-04-15
LU91658I2 (fr)	2010-05-03
JP3626996B2 (ja)	2005-03-09
CN1313152C (zh)	2007-05-02
NO944475L (no)	1995-01-18
SK142194A3 (en)	1995-08-09
DK0642355T3 (da)	1998-11-30
ATE168271T1 (de)	1998-08-15
FI945483L (fi)	1995-01-20
DE122010000016I1 (de)	2010-07-08
ES2118963T3 (es)	1998-10-01
SG48365A1 (en)	1998-04-17
AU785433B2 (en)	2007-05-31
CY2614B2 (en)	2012-01-25
DE69319728D1 (de)	1998-08-20
JPH07508267A (ja)	1995-09-14

Publication	Publication Date	Title
MA22894A1 (fr)	1993-12-31	Procede de preparation d'un vaccin.
MA22842A1 (fr)	1993-10-01	Procede de preparation de compositions de vaccin.
MA22626A1 (fr)	1993-04-01	Procede de preparation d'acides imidazolyl-alcenoiques .
MA22668A1 (fr)	1993-07-01	Procede de preparation d'oxamides .
MA21682A1 (fr)	1990-07-01	Procede de preparation d'agents therapeutiques derives de la quainclidine.
MA22481A1 (fr)	1992-12-31	Procede de preparation d'acides imidazolyl - alcenoiques .
MA22471A1 (fr)	1992-10-01	Procede de production de vaccin
FR2621785B1 (fr)	1993-12-10	Procede de preparation d'un roux
FR2689887B1 (fr)	1995-06-23	Procede de preparation d'un derive de biphenyle.
FR2707087B1 (fr)	1995-10-13	Nouveau procédé de préparation de l'ergothionéine.
FR2678104B1 (fr)	1995-05-24	Procede d'extraction combinee transuraniens-strontium.
MA22443A1 (fr)	1992-10-01	Procede de preparation d'une composition pharmaceutique .
DZ1569A1 (fr)	2002-02-17	Procédé de préparation de ginkgolide b a partir deginkgolide c.
ITTO910894A0 (it)	1991-11-21	"un procedimento per preparare dipeptidi".
DZ1687A1 (fr)	2002-02-17	Procédé d'extraction par membrane.
FR2708266B1 (fr)	1997-01-10	Procédé de préparation d'alcanesulfonamides.
MA21854A1 (fr)	1990-12-31	Procede de preparation de phosphonomethyl thioethoxypurines .
FI933755A7 (fi)	1993-08-26	Menetelmä trans-piperidiini-2,5-dikarboksylaattien valmistamiseksi
FR2630735B1 (fr)	1990-09-14	Procede de preparations d'halogenophenols
NO179101C (no)	1996-08-07	Fremgangsmåte for fremstilling av dibeskyttet 2,3-hydroksymetyl-cyklobutanol
FI97542B (fi)	1996-09-30	Uusi menetelmä 9-amino-1,2,3,4-tetrahydroakridiinien valmistamiseksi
HUT71953A (en)	1996-02-28	A process for the preparation of 2,3,5,6-tetrachloro-pyridine
FR2615185B1 (fr)	1990-05-25	Procede de preparation de trifluoromethyltoluene a partir d'halomethylbenzotrifluorure
FI930237A7 (fi)	1993-07-24	Menetelmä 4,6-dialkoksipyrimidiinien valmistamiseksi
EP0643724A4 (fr)	1995-05-10	Procede d'elaboration de 3-carbonylandrostadiene 17-carboxamides.